The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients

A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients

(2013) Shaohua Hu et al.   PSYCHOPHARMACOLOGY

Mortality risk of triglyceride levels in patients with coronary artery disease

(2012) Takatoshi Kasai et al.   HEART

Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia

(2012) Jian-Jun Ou et al.   PSYCHOPHARMACOLOGY

Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters

(2012) Kieran J. Davey et al.   PSYCHOPHARMACOLOGY

Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder

(2011) Leslie Citrome et al.   CLINICAL DRUG INVESTIGATION

Oral dehydroepiandrosterone replacement in older adults: effects on central adiposity, glucose metabolism and blood lipids

(2011) Catherine M. Jankowski et al.   CLINICAL ENDOCRINOLOGY

Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat

(2011) Goran Jassim et al.   PSYCHOPHARMACOLOGY

Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: A multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA

(2009) Michael S. Ritsner et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS)

(2008) Nicole Maninger et al.   FRONTIERS IN NEUROENDOCRINOLOGY

Dehydroepiandrosterone prevents age-associated alterations, increasing insulin sensitivity

(2008) Juana Sánchez et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY